Senkoro Elizabeth, Muwonge Timothy, Samson Leila, Kasiita Vicent, Nalumansi Alisaati, Kamusiime Brenda, Mollel Gertrude, Weisser Maja, Mujugira Andrew
Ifakara Health Institute, Chronic Disease Clinic of Ifakara, Morogoro, Tanzania.
Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
BMC Public Health. 2025 Aug 20;25(1):2854. doi: 10.1186/s12889-025-24120-1.
BACKGROUND: HIV serodifferent couples where one partner is living with HIV and the other is not, remain a key population for HIV prevention. Maintaining an undetectable viral load eliminates the risk of sexual HIV transmission, this principle is often summarised as undetectable = untransmittable (U = U). However, the extent to which this principle is understood and utilised by serodifferent couples remains unclear. This study aimed to explore both partners’ perceptions, experiences and adoption of U = U within their relationships. METHODS: We conducted an exploratory qualitative study using in-depth interviews with 20 serodifferent couples (40 participants) between July and August 2023 in Ifakara, Tanzania and Kasangati, Uganda. Each partner was interviewed separately. Interviews explored: (1) Awareness of U = U, (2) Lived experiences related to U = U, and (3) Social perceptions of U = U and HIV serodifference. The interviews were audio-recorded, transcribed, and analysed using thematic analysis with Atlas.ti for coding. RESULTS: All participants were in a heterosexual serodifferent relationship and had mutually disclosed their status. The average age was 25 years, and couples had been partnered for approximately 3.5 years. All 40 participants (100%) had basic knowledge of U = U or treatment as prevention. The qualitative analysis identified four key themes that were broadly consistent in both settings: (1) Knowledge of U = U facilitated adoption, with initial doubts giving way to trust over time as partners remained HIV-negative; (2) Disclosure triggered emotional responses, which were alleviated through counselling, with U = U influencing relationship confidence and fertility decisions; (3) Use of additional prevention (PrEP, condoms) reinforced trust in U = U, addressing residual concerns about adherence and fidelity; (4) Persistent stigma and limited community awareness constrained U = U’s potential impact. Themes were largely consistent across Uganda and Tanzania, though Ugandan participants more frequently reported detailed provider counselling and PrEP use. CONCLUSION: This study highlights how understanding experiences of U = U among HIV serodifferent couples in Tanzania and Uganda are shaped by personal, relational, and contextual factors. Our findings suggest that U = U communication strategies should be strengthened through context-specific counselling, improved access to viral load testing, and community education. Further research is needed to explore how U = U is perceived and adopted in more diverse settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-025-24120-1.
背景:一方感染艾滋病毒而另一方未感染的血清学不同的伴侣,仍然是艾滋病毒预防的重点人群。保持病毒载量不可检测可消除性传播艾滋病毒的风险,这一原则通常概括为“不可检测即不可传播”(U=U)。然而,血清学不同的伴侣对这一原则的理解和应用程度仍不清楚。本研究旨在探讨双方在其关系中对“不可检测即不可传播”原则的看法、经历和采用情况。 方法:2023年7月至8月,我们在坦桑尼亚的伊法卡拉和乌干达的卡萨恩加蒂对20对血清学不同的伴侣(40名参与者)进行了深入访谈,开展了一项探索性定性研究。每位伴侣分别接受访谈。访谈探讨了:(1)对“不可检测即不可传播”原则的认识;(2)与“不可检测即不可传播”原则相关的生活经历;(3)对“不可检测即不可传播”原则和艾滋病毒血清学差异的社会认知。访谈进行了录音、转录,并使用Atlas.ti进行编码的主题分析。 结果:所有参与者均处于异性血清学不同的关系中,且相互披露了自己的感染状况。平均年龄为25岁,伴侣关系约为3.5年。所有40名参与者(100%)都对“不可检测即不可传播”原则或治疗即预防有基本了解。定性分析确定了在两种环境中大致一致的四个关键主题:(1)对“不可检测即不可传播”原则的了解促进了其采用,随着伴侣保持艾滋病毒阴性,最初的疑虑逐渐被信任取代;(2)披露引发了情绪反应,通过咨询得以缓解,“不可检测即不可传播”原则影响了关系信心和生育决定;(3)使用额外的预防措施(暴露前预防、避孕套)增强了对“不可检测即不可传播”原则的信任,解决了对依从性和忠诚性的残留担忧;(4)持续的耻辱感和社区意识有限限制了“不可检测即不可传播”原则的潜在影响。尽管乌干达参与者更频繁地报告了详细的提供者咨询和暴露前预防的使用情况,但这些主题在乌干达和坦桑尼亚基本一致。 结论:本研究强调了坦桑尼亚和乌干达血清学不同的艾滋病毒伴侣对“不可检测即不可传播”原则的体验是如何受到个人、关系和背景因素影响的。我们的研究结果表明,应通过针对具体情况的咨询、改善病毒载量检测的可及性和社区教育来加强“不可检测即不可传播”原则的沟通策略。需要进一步研究以探索在更多样化的环境中“不可检测即不可传播”原则是如何被认知和采用的。 补充信息:在线版本包含可在10.1186/s12889-025-24120-1获取的补充材料。
PLOS Glob Public Health. 2024-3-7
PLOS Glob Public Health. 2022-8-17
J Int AIDS Soc. 2022-3
J Acquir Immune Defic Syndr. 2021-10-1